natgillin/translations-raw huggingface dataset:
Administration of miglustat to male and female Sprague-Dawley rats by oral gavage for 2 years at dose levels of 30, 60 and 180 mg/kg/day resulted in an increased incidence of testicular interstitial cell (Leydig cell) hyperplasia and adenomas in male rats at all dose levels.
Primjena miglustata kod muških i ženskih Sprague-Dawley štakora oralnom sondom tijekom 2 godine u dozama od 30, 60 i 180 mg/kg/dan za rezultat je imala povećanu incidenciju hiperplazije testikularnih intersticijskih stanica (Leydigove stanice) i adenoma u muških štakora pri svim razinama doza.
INFORMATION IN BRAILLE Yargesa 100 mg
Yargesa 100 mg
- If you have any further questions, ask your doctor or pharmacist.
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
Do not take this medicine after the expiry date which is stated on the blister and carton after ‘EXP'.
Ovaj lijek se ne smije upotrijebit nakon isteka roka valjanosti navedenog na kutiji iza oznake „Rok valjanosti“.
3 Push product through foil
Gurnite lijek kroz foliju
The inhibitory action on glucosylceramide synthase forms the rationale for substrate reduction therapy in Gaucher disease.
Inhibitorno djelovanje na glukozilceramid sintazu predstavlja logičku podlogu za liječenje smanjenjem supstrata kod Gaucherove bolesti.
A mean increase in haemoglobin concentration of 0.26 g/dl and a mean platelet count increase of 8.29 × 109/l were observed.
Uočeno je prosječno povećanje koncentracije hemoglobina za 0,26 g/dl i prosječno povećanje broja trombocita za 8,29 × 109/l.
The usual dose of Yargesa in adult patients was 200 mg t.i.d., and was adjusted according to body surface area in paediatric patients.
Uobičajena doza Yargesa u odraslih bolesnika bila je 200 mg triput dnevno, a kod pedijatrijskih bolesnika je bila prilagođena veličini površine tijela.
Weight loss, decreased appetite
Gubitak težine, smanjen apetit Psihijatrijski poremećaji Često
29 patients continued in the extension period.
Dvadeset i devet bolesnika nastavilo je s liječenjem u razdoblju nastavka.
If you forget to take Yargesa
Ako ste zaboravili uzeti lijek Yargesa
Diarrhoea, flatulence, abdominal pain
Proljev, flatulencija, bolovi u trbuhu
Printing ink shellac glaze iron oxide black (E172) propylene glycol concentrated ammonia solution
Tinta za označavanje šelak glazura, željezov oksid, crni (E172) propilenglikol, koncentrirana otopina amonijaka.
Until further information is available, before seeking to conceive, male patients should cease Yargesa and maintain reliable contraceptive methods for a further 3 months.
Do dostupnosti daljnjih informacija, prije pokušaja začetka djeteta, muški bolesnici trebaju prekinuti uzimanje lijeka Yargesa i primjenjivati pouzdane metode kontracepcije daljnja 3 mjeseca.
Each hard capsule contains 100 mg miglustat.
Svaka tvrda kapsula sadrži 100 mg miglustata.
Studies in the rat have shown that miglustat adversely affects spermatogenesis and sperm parameters, and reduces fertility (see sections 4.6 and 5.3).
Ispitivanja na štakorima pokazala su da miglustat štetno djeluje na spermatogenezu i parametre sperme, te da umanjuje plodnost (vidjeti dijelove 4.6 i 5.3).
The benefit of treatment with Yargesa for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be reappraised after at least 1 year of treatment with Yargesa, (see section 4.4).
Korist od liječenja Yargesa kod neuroloških manifestacija u bolesnika s Niemann-Pickovom bolesti tipa C treba redovito ocjenjivati, npr. svakih 6 mjeseci; nastavak liječenja treba ponovo procijeniti nakon najmanje 1 godine liječenja Zavescom (vidjeti dio 4.4).
The pharmacokinetics of miglustat is similar in adult type 1 Gaucher disease patients and Niemann-Pick type C disease patients when compared to healthy subjects.
Farmakokinetika miglustata slična je onoj u odraslih bolesnika s Gaucherovom bolesti tipa 1 i NiemannPickovom bolesti tipa C kada se usporedi sa zdravim osobama.
Weight loss has been reported in 55% of patients using miglustat.
U 55 % bolesnika liječenih miglustatom zabilježen je gubitak tjelesne težine.
In patients with type 1 Gaucher disease, monitoring of platelet counts is recommended.
Kod bolesnika s Gaucherovom bolesti tipa 1 preporučuje se praćenje broja trombocita.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 100 mg miglustat.
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tvrda kapsula sadržava 100 mg miglustata.
Studies in the rat have shown that miglustat adversely affects sperm parameters (motility and morphology) thereby reducing fertility (see sections 4.4 and 5.3).
Ispitivanja na štakorima su pokazala da miglustat štetno djeluje na parametre sperme (motilitet i morfologiju) te umanjuje plodnost (vidjeti dijelove 4.4 i 5.3).
Yargesa works by inhibiting the enzyme called ‘glucosylceramide synthase' which is responsible for the first step in the synthesis of most glycosphingolipids.
Yargesa djeluje kao inhibitor enzima 'glukozilceramid sintaze', odgovornog za prvi korak u sintezi većine glikosfingolipida.
Nausea, vomiting, abdominal distension/discomfort, constipation, dyspepsia Musculoskeletal and connective tissue disorders Common
Mučnina, povraćanje, abdominalna distenzija/nelagoda, konstipacija, dispepsija Poremećaji mišićno-koštanog sustava i vezivnog tkiva Često
• Yargesa is used to treat mild to moderate type 1 Gaucher disease in adults.
• Yargesa se primjenjuje za liječenje blage do umjerene Gaucherove bolesti tipa 1 u odraslih.
NAME OF THE MARKETING AUTHORISATION HOLDER Piramal Critical Care B.V.
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Piramal Critical Care B.V.
Temporary dose reduction to 100 mg once or twice a day may be necessary in some patients because of diarrhoea.
Kod nekih će bolesnika možda biti potrebno privremeno smanjenje doze na 100 mg jedanput ili dvaput dnevno, zbog proljeva.
Thrombocytopenia Metabolism and nutrition disorders Very common
Poremećaji metabolizma i prehrane Vrlo često
Small mean reductions in haemoglobin [-0.95 g/dL (95% CI: -1.38, -0.53)] and platelet count [-44.1 × 109/L (95% CI: -57.6, -30.7)] were observed between baseline and end of study.
Između početka i kraja ispitivanja uočeno je malo prosječno smanjenje hemoglobina [-0,95 g/dL (95% CI: -1,38; -0,53)] i broja trombocita [-44,1 × 109/L (95% CI: -57,6; -30,7)].
Miglustat has been administered at doses of up to 3000 mg/day for up to six months in HIV positive patients during clinical trials.
Miglustat je u kliničkim ispitivanjima kod HIV pozitivnih bolesnika primjenjivan u dozama do 3 000 mg/dan tijekom najviše šest mjeseci.
Breast-feeding It is not known if miglustat is secreted in breast milk.
Nije poznato izlučuje li se miglustat u majčino mlijeko.
Common side effects of treatment include headache, dizziness, paraesthesia (tingling or numbness), abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea (feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and thrombocytopenia (reduced levels of blood platelets).The neurological symptoms and thrombocytopenia could be due to the underlying disease.
Česte nuspojave liječenja uključuju glavobolju, omaglicu, paresteziju (trnci ili obamrlost), poremećenu koordinaciju, hipoesteziju (oslabljen osjet na dodir), dispepsiju (žgaravica), mučninu, zatvor i povraćanje, oticanje ili nelagoda u abdomenu (trbuhu) i trombocitopeniju (smanjenje broja trombocita).
Adverse events observed included granulocytopenia, dizziness and paraesthesia.
Primijećeni su štetni događaji koji uključuju granulocitopeniju, omaglicu i paresteziju.
INSTRUCTIONS ON USE
15. UPUTE ZA UPOTREBU
Do not drive or use any tools or machines if you feel dizzy.
Ako osjećate omaglicu, nemojte voziti niti raditi sa alatima i strojevima.
The apparent volume of distribution of miglustat is 83 l. Miglustat does not bind to plasma proteins.
Prividni volumen distribucije miglustata je 83 l.
In 11 clinical trials in different indications 247 patients were treated with miglustat at dosages of 50-200 mg t.i.d.
U 11 kliničkih ispitivanja s različitim indikacijama 247 bolesnika je liječeno Yargesa u dozama od 50-200 mg triput dnevno, u prosječnom trajanju od 2,1 godine.
Marketing Authorisation Holder and Manufacturer Piramal Critical Care B.V.
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač: Piramal Critical Care B.V.
There was a mean increase of 22.2 × 109/l in platelet count, and a mean increase of 0.95 g/dl in haemoglobin concentration.
Uočeno je prosječno povećanje broja trombocita od 22,2 × 109/l i prosječno povećanje koncentracije hemoglobina od 0,95 g/dl.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
U slučaju bilo kakvih pitanja u vezi s primjenom ovoga lijeka, obratite se liječniku ili ljekarniku.
Type 1 Gaucher disease
Gaucherova bolest tipa 1
Until further information is available, it is advised that before seeking to conceive, male patients should cease Yargesa and maintain reliable contraceptive methods for 3 months thereafter.
Do dostupnosti daljnjih informacija savjetuje se muškim bolesnicima da prije pokušaja začeća djeteta prekinu uzimanje lijeka Yargesa i primjenjuju pouzdane metode kontracepcije daljnja 3 mjeseca.
The recommended starting dose for the treatment of adult patients with Type 1 Gaucher disease is 100 mg three times a day.
Preporučena početna doza za liječenje odraslih bolesnika s Gaucherovom bolesti tipa 1 je 100 mg triput dnevno.
The recommended dose for the treatment of adolescent patients (12 years of age and above) with NiemannPick type C disease is 200 mg three times a day.
Preporučena doza za liječenje adolescentnih bolesnika (12 godina i starijih) s Niemann-Pickovom bolesti tipa C je 200 mg triput dnevno.
In patients with an adjusted creatinine clearance of 50-70 ml/min/1.73 m2, administration should commence at a dose of 100 mg twice daily in patients with type 1 Gaucher disease and at a dose of 200 mg twice daily (adjusted for body surface area in patients below the age of 12) in patients with Niemann-Pick type C disease.
Kod bolesnika s prilagođenim klirensom kreatinina od 50-70 ml/min/1,73 m2, primjenu treba početi s dozom od 100 mg dvaput dnevno u bolesnika s Gaucherovom bolesti tipa 1, te dozom od 200 mg dvaput dnevno (prilagođeno površini tijela u bolesnika mlađih od 12 godina) u bolesnika s Niemann-Pickovom bolesti tipa C.
Due to limited experience, Yargesa should be used with caution in patients with renal or hepatic impairment.
Zbog ograničenog iskustva, kod bolesnika s poremećajem funkcije bubrega ili jetre, lijek Yargesa treba koristiti oprezno.
Therapy should be directed by physicians who are knowledgeable in the management of Gaucher disease or Niemann-Pick type C disease, as appropriate.
Liječenje trebaju voditi liječnici s odgovarajućim iskustvom u liječenju Gaucherove bolesti ili NiemannPickove bolesti tipa C.
In patients with an adjusted creatinine clearance of 30-50 ml/min/1.73 m2, administration should commence at a dose of 100 mg once daily in patients with type 1 Gaucher disease and at a dose of 100 mg twice daily (adjusted for body surface area in patients below the age of 12) in patients with Niemann-Pick type C disease.
Kod bolesnika s prilagođenim klirensom kreatinina od 30-50 ml/min/1,73 m2, primjenu treba početi s dozom od 100 mg jednom dnevno u bolesnika s Gaucherovom bolesti tipa 1, te dozom od 100 mg dvaput dnevno (prilagođeno površini tijela u bolesnika mlađih od 12 godina) u bolesnika s Niemann-Pickovom bolesti tipa C.
How to take Yargesa
Kako uzimati lijek Yargesa
The recommended dose for the treatment of adult patients with Niemann-Pick type C disease is 200 mg three times a day.
Preporučena doza za liječenje odraslih bolesnika s Niemann-Pickovom bolesti tipa C je 200 mg triput dnevno.
Male patients should use reliable birth control methods during their treatment with Yargesa and for 3 months after finishing treatment.
Muški bolesnici trebaju primjenjivati pouzdane metode kontracepcije tijekom liječenja lijekom Yargesa, te još 3 mjeseca nakon završetka liječenja.
Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.
Yargesa je indicirana za peroralno liječenje odraslih bolesnika s blagom do umjerenom Gaucherovom bolesti tipa
There were no events of bone crisis, avascular necrosis or fracture during the treatment period.
Tijekom razdoblja liječenja nije bilo koštanih kriza, avaskularnih nekroza niti lomova.
A total daily dose of 300 mg miglustat administered in three divided doses was used in the above two studies.
U gornja dva ispitivanja primijenjena je ukupna dnevna doza miglustata od 300 mg u tri pojedinačne doze.
Monitoring of platelet counts is recommended in these patients.
U tih se bolesnika preporučuje praćenje broja trombocita.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Lijek se izdaje na ograničeni recept (vidjeti Prilog I: Sažetak opisa svojstava lijeka, dio 4.2)
Dosage in type 1 Gaucher disease
Doziranje kod Gaucherove bolesti tipa 1 Odrasli
How to store Yargesa
Kako čuvati lijek Yargesa
The hard capsule consists of an opaque white cap and body with “708” printed in black on the body.
Tvrda kapsula sastoji se od neprozirne bijele kapice i tijela na kojem je otisnuto „708” crnom bojom Veličina kapsule: 4 (14,3 mm x 5,3 mm)
Hepatic Impairment Yargesa has not been evaluated in patients with hepatic impairment.
Lijek Yargesa nije procjenjivan kod bolesnika s oštećenjem funkcije jetre.
Bone manifestations of type 1 Gaucher disease were evaluated in 3 open-label clinical studies in patients treated with miglustat 100 mg t.i.d.
Manifestacije Gaucherove bolesti tipa 1 na kostima ocjenjivane su u 3 otvorena klinička ispitivanja u bolesnika liječenih miglustatom 100 mg triput dnevno u trajanju do 2 godine (n = 72).
Fatigue, asthenia, chills and malaise
Umor, astenija, zimica i malaksalost
NAME OF THE MEDICINAL PRODUCT Yargesa 100 mg hard capsules
Yargesa 100 mg tvrde kapsule
NAME OF THE MEDICINAL PRODUCT Yargesa 100 mg hard capsules miglustat
Yargesa 100 mg tvrde kapsule miglustat
Dosage in Niemann-Pick type C disease
Doziranje kod Niemann-Pickove bolesti tipa C Odrasli
Temporary dose reduction may be necessary in some patients because of diarrhoea.
Kod nekih će bolesnika možda biti potrebno privremeno smanjenje doze zbog proljeva.
• if you suffer from kidney disease • if you suffer from liver disease
Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Yargesa - ako patite od bolesti bubrega ako patite od bolesti jetre
Adverse reactions were generally of mild to moderate severity and occurred with similar frequency across indications and dosages tested.
I javljale su se sličnom učestalošću kod svih ispitivanih indikacija i doziranja.
Although no direct comparisons with Enzyme Replacement Therapy (ERT) have been performed in treatment-naive patients with type 1 Gaucher disease, there is no evidence of miglustat having an efficacy or safety advantage over ERT. ERT is the standard of care for patients who require treatment for type 1 Gaucher disease (see section 5.1).
Enzyme Replacement Therapy, ERT) u liječenju bolesnika s Gaucherovom bolesti tipa 1, nema dokaza da je miglustat djelotvorniji ili sigurniji od ERT-a.
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains 100 mg miglustat.
NAVOĐENJE DJELATNE(IH) TVARI Svaka tvrda kapsula sadržava 100 mg miglustata
• For type 1 Gaucher disease: For adults, the usual dose is one capsule (100 mg) three times a day (morning, afternoon and evening).
Doziranje Za Gaucherovu bolest tipa 1: za odrasle je uobičajena doza jedna kapsula (100 mg) tri puta dnevno
The pivotal trial of miglustat was conducted in patients unable or unwilling to receive ERT. Reasons for not receiving ERT included the burden of intravenous infusions and difficulties in venous access.
Ključno ispitivanje miglustata provedeno je na bolesnicima koji nisu mogli ili nisu željeli primati ERT.
The patients were switched to monotherapy with miglustat 100 mg t.i.d.
Bolesnici su prešli na monoterapiju miglustatom 100 mg triput dnevno.
Mild reductions in platelet counts without association with bleeding were observed in patients with type 1 Gaucher disease who were switched from ERT to miglustat.
Kod bolesnika s Gaucherovom bolesti tipa 1 koji su s ERT-a prešli na miglustat primijećena su blaga smanjenja broja trombocita, a koja nisu povezana s krvarenjem.
Gastrointestinal disorders Very common
Poremećaji probavnog sustava Vrlo često
Mild reductions in platelet counts without association to bleeding were observed in some patients with Niemann-Pick type C disease treated with Yargesa.
Kod nekih bolesnika s Niemann-Pickovom bolesti tipa C liječenih Yargesa primijećena su mala smanjenja broja trombocita, a koja nisu povezana s krvarenjem.
Some patients have had tingling or numbness in the hands and feet (seen commonly).
Neki bolesnici osjećaju trnce ili obamrlost u šakama i stopalima (česta pojava).
Management
Postupanje
Nerve conduction studies abnormal
Poremećeni nalazi ispitivanja provodljivosti živaca
You must use effective birth control while taking Yargesa.
Dok uzimate lijek Yargesa morate primjenjivati učinkovitu kontracepciju.
adjusted for body surface area resulted in Cmax and AUCτ values which were approximately twofold those attained after 100 mg t.i.d.
Doziranje u djece od 200 mg triput dnevno prilagođeno veličini površine tijela dalo je vrijednosti Cmax i AUCτ koje su približno dvostruke od onih dobivenih nakon 100 mg triput dnevno u bolesnika s Gaucherovom bolesti tipa 1, što je sukladno farmakokinetici miglustata linearno ovisnoj o dozi.
Muscle spasms, muscle weakness General disorders and administration site reactions Common
Mišićni spazmi, slabost u mišićima
DATE OF REVISION OF THE TEXT
DATUM PRVOG ODOBRENJA/DATUM OBNOVE ODOBRENJA
If you get any side effects, talk to your doctor or pharmacist.
Ako primijetite bilo koju nuspojavu, potrebno je obavijesti liječnika ili ljekarnika.
Dosage
Dojenje
for an average duration of 2.1 years.
6.3 Rok valjanosti
Subcutaneous or intravenus use
Subcutaneous, Intramuscular or Intravenous use
Dogs and cats
Cattle, pigs and horses
Bottle (Glass with measuring syringe (LDPE)
Polietilena visoke gustoće bočicu + jednom graduiranom brizgalice
Target species
Meloxidyl
1 ml (180 µg/ml) 4 vials
1 ml (180 µg/ml) 4 bočice
1 ml (180 µg/ml) 1 vial
1 ml (180 µg/ml) 1 bočica
Strength Pharmaceutical Form
Otopina za injekciju
This will prevent infections.
To će spriječiti infekcije.
These changes may be permanent.
Ove promjene mogu biti trajne.
Tilt your head back and look at the ceiling.
Zabacite glavu unazad i gledajte prema stropu.
Put your next dose in at the usual time.
Primijenite sljedeću dozu u uobičajeno vrijeme.
Risk Management Plan (RMP)
• Plan upravljanja rizikom (RMP)
You should not drive or use machines until your sight is clear again.
Ne biste smjeli upravljati vozilima ili strojevima dok ponovno jasno ne vidite.
The duration of effect is maintained for at least 24 hours.
Učinak traje najmanje 24 sata.
The following pack sizes are available:
Dostupne su sljedeće veličine pakiranja:
Other medicines and LUMIGAN
Drugi lijekovi i LUMIGAN
The frequency of these symptoms is not known.
Učestalost ovih simptoma nije poznata.
No interaction studies have been performed.
Nisu provedena ispitivanja interakcija.
If overdose occurs, treatment should be symptomatic and supportive.
Ako dođe do predoziranja, liječenje treba biti simptomatsko i potporno.
• An increase in blood-test results that show how your liver is working
• Povišeni rezultati krvnih pretraga koje pokazuju kako radi Vaša jetra
The change may be more noticeable if you are only treating one eye.
Promjena bi mogla biti uočljivija ako liječite samo jedno oko.
It belongs to a group of medicines called prostamides.
Pripada skupini lijekova koju nazivamo prostamidima.
For single use only, one container is sufficient to treat both eyes.
Samo za jednokratnu uporabu; jedan spremnik dovoljan je za oba oka.
• Increased blood pressure
• Povišeni krvni tlak
For single use only
Samo za jednokratnu uporabu
Other Information
Ostale informacije
To help you remember, write down the date you opened it in the space on the box.
Kako biste lakše zapamtili, zabilježite datum kada ste je otvorili u za to predviđen prostor na kutiji.
• Small breaks in the surface of the eye, with or without inflammation
• Male pukotine na površini oka, sa ili bez upale
This medicine may be used on its own or with other drops called beta-blockers which also reduce pressure.
Ovaj lijek možete koristiti sam ili uz druge kapi koje se zovu beta-blokatori i koje također smanjuju tlak.
Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated.
Neke od tih promjena mogu biti trajne i mogu dovesti do različitog izgleda očiju ako se liječi samo jedno oko.
Do not use more than once a day as the effectiveness of treatment may be reduced.
Nemojte koristiti češće od jedanput dnevno jer bi učinkovitost liječenja mogla biti smanjena.
In human blood, bimatoprost resides mainly in the plasma.
U ljudskoj krvi, bimatoprost se većinom nalazi u plazmi.
Reduction of the intraocular pressure starts approximately 4 hours after the first administration and maximum effect is reached within approximately 8 to 12 hours.
Sniženje intraokularnog tlaka započinje otprilike 4 sata nakon prve primjene, a maksimalan učinak se postiže u roku od otprilike 8 do 12 sati.
Animal studies have shown reproductive toxicity at high maternotoxic doses (see section 5.3).
Ispitivanja na životinjama pokazala su reproduktivnu toksičnost pri visokim maternotoksičnim dozama (vidjeti dio 5.3).
Do not store above 25°C.
POSEBNE MJERE ČUVANJA Ne čuvati na temperaturi iznad 25°C.
LUMIGAN should not be used during pregnancy unless clearly necessary.
LUMIGAN se ne bi trebao koristiti tijekom trudnoće osim ako je to izričito neophodno.
There was no accumulation of bimatoprost in the blood over time and the safety profile was similar in elderly and young patients.
Nije došlo do akumulacije bimatoprosta u krvi tijekom vremena, a sigurnosni profil bio je sličan kod starijih i mlađih pacijenata.
This is enough for 4 weeks' usage.
To je dovoljno za 4-tjednu primjenu.
Your eye contains a clear, watery liquid that feeds the inside of the eye.
Vaše oko sadrži prozirnu, vodenastu tekućinu koja hrani unutrašnjost oka.
Increased iris pigmentation is likely to be permanent.
Pojačana pigmentacija šarenice vjerojatno će biti trajna.
For any information about this medicine, please contact the local representative of the marketing authorisation holder.
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet:
• Sensitivity to light
• Osjetljivost na svjetlost
The plasma protein binding of bimatoprost is approximately 88 %.
Vezivanje bimatoprosta na proteine plazme iznosi otprilike 88%.
• An allergic reaction in the eye
• Alergijska reakcija u oku
If a drop misses your eye, try again.
Ako kap promaši oko, ponovite postupak.
LUMIGAN has negligible influence on the ability to drive and use machines.
LUMIGAN zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Bimatoprost selectively mimics the effects of newly discovered biosynthesised substances called prostamides.
Bimatoprost selektivno imitira učinke novootkrivenih biosintetiziranih tvari koje se nazivaju prostamidi.
After ocular administration in adults, the systemic exposure of bimatoprost is very low with no accumulation over time.
Nakon primjene u oko odraslih osoba, sistemska izloženost bimatoprostu je vrlo niska bez akumulacije tijekom vremena.
It is a synthetic prostamide, structurally related to prostaglandin F2 (PGF2), that does not act through any known prostaglandin receptors.
Radi se o sintetskom prostamidu, strukturno srodnom prostaglandinu F2 (PGF2) koji ne djeluje preko poznatih prostaglandinskih receptora.